ClinicalTrials.gg
CompletedNCT04330001Updated May 6, 2023

Exploratory Clinical Study for Techniques Associated With the Fluid Accommodating IOL

An interventional study of Alcon Fluid Accommodating Intraocular Lens and Top Con Autorefractor in Aphakia and Presbyopia, sponsored by Alcon Research. Completed at 2 sites in 2 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2023-05-06.

Sponsored by Alcon Research (part of Alcon) · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
99
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to assess the repeatability of objective refraction using auto refraction on subjects bilaterally implanted (implanted in both eyes) with the Fluid Accommodating IOL (FAIOL).

Read the detailed description

Subjects will be expected to attend 10 office visits from screening to exit. The total expected duration of participation for each subject in this study is approximately 12 months. The second eye surgery will take place within 7-15 days from the date of the first implanted eye. The primary endpoint will be collected at Month 1, following the 2nd eye implant date.

02

Conditions studied

  • Aphakia
  • Presbyopia

Keywords

  • IOL
  • Cataract
  • Accommodation
03

In context

Aphakia

69 studies on the registry are indexed under Aphakia; 6 are open to participants now.

This study's enrollment of 99 is close to the median of 103 across 52 interventional studies indexed under Aphakia.

Browse Aphakia studies →

Lead sponsor

Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.

Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to attend all scheduled study visits as required per protocol
  • 22 years of age or older
  • Bilateral cataracts
  • Corneal astigmatism ≤ 1.25 D
  • Clear intraocular media other than cataract
  • Other protocol-specified inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Women of , defined as all women who are physiologically capable of becoming pregnant and who are not for at least 1 year or are less than 6 weeks since sterilization, are excluded from participation if any of the following apply:

    1. are currently pregnant,
    2. have a positive urine pregnancy test result at V0,
    3. intend to become pregnant during the study period,
    4. are breast-feeding.
  • Subjects taking medications that may affect accommodation, confound the outcome, or as per the Investigator's opinion may increase the risk to the subject
  • Glaucoma
  • Significant corneal or retinal abnormalities, per the Investigator's opinion, or other disease or pathology other than cataract expected to reduce postoperative vision
  • Monocular patient, significant permanent visual function loss, or binocular vision anomalies as evaluated by specific testing
  • Previous corneal procedure (such as LASIK, keratotomy, LRI) or plans to have additional corneal procedures during the study
  • Systemic disease that could increase the operative risk or confound the outcome
  • Other protocol-specified exclusion criteria may apply
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    FAIOL

    Implantation of FAIOL in the capsular bag in the posterior chamber of the eye. The IOL is intended to be used over the lifetime of the subject.

    Device: Alcon Fluid Accommodating Intraocular Lens · Other: Top Con Autorefractor

Interventions

  • DeviceAlcon Fluid Accommodating Intraocular Lens

    Intraocular lens intended to treat presbyopia by dynamically adjusting power, resulting in a continuous range of vision from distance to near.

    Also known as: FAIOL, FluidVision MX Accommodating IOL

  • OtherTop Con Autorefractor

    Device intended to automatically determine the focusing characteristics of the eye

06

What researchers measure

Primary outcomes

  1. Repeatability of objective refraction

    Two assessments of objective refraction (sphere, cylinder, and spherical equivalent) using auto refraction will be made on the same day. Repeatability of objective refraction will be evaluated using the Intra-class correlation coefficient (ICC), separately by eye. ICC is evaluated as the proportion of all variation that is not due to measurement error. Higher values of ICC indicate lower error variance and hence better repeatability. Repeatability of objective refraction will be assessed with and without cycloplegia (temporary paralysis of the ciliary muscle).

    Time frame: Month 1 (post 2nd eye implant)

07

Study locations

2 sites
  • Alcon Investigator 8071
    San Salvador, 4625, El Salvador
  • Alcon Investigator 8165
    Panamá, Panama
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04330001
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 1, 2020
Start date
Dec 28, 2020
Primary completion
Jun 8, 2022
Completion
May 3, 2023
Last update
May 6, 2023

Study contacts

Clinical Operation Lead CDMA Surgical
study director · Alcon Research

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion